Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3678013 | 1.00 | NPC1 (0.56) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL30426579 | 1.00 | NPC1 (0.56) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL28344271 | 1.00 | NPC1 (0.56) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL23912877 | 0.85 | NPC1 (0.41) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL22444733 | 0.85 | NPC1 (0.55) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7171153 | 0.83 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7176406 | 0.83 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7171650 | 0.83 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7176410 | 0.83 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7182624 | 0.83 | NPC1 (0.62) | NPC1SMN1; SMN2RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117623925-A | Method for deoxidizing and converting photocatalytic alcohol | 同济大学 | 2024-03-01 | — | — | CN | claimed |
| CN-116444400-A | Chiral alpha- (trichloromethyl) amine compound and preparation method thereof | 合肥工业大学 | 2023-07-18 | — | — | CN | claimed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| CN-117623925-A | Method for deoxidizing and converting photocatalytic alcohol | 同济大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-116444400-A | Chiral alpha- (trichloromethyl) amine compound and preparation method thereof | 合肥工业大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-111039916-B | Tricyclic spiro compounds | 小野药品工业株式会社 | 2023-04-28 | — | — | CN | disclosed |
| CN-115397824-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109475520-B | Combinations comprising an EP4 antagonist and an immune checkpoint inhibitor | 小野药品工业株式会社 | 2021-05-14 | — | — | CN | disclosed |
| CN-111039916-A | Tricyclic spiro compounds | 小野药品工业株式会社 | 2020-04-21 | — | — | CN | disclosed |
| CN-107108480-B | Tricyclic spiro compounds | 小野药品工业株式会社 | 2020-01-17 | — | — | CN | disclosed |
| US-8586498-B2 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2095875-A1 | Homogeneous asymmetric hydrogenation catalyst | Takasago International Corporation (JP) | 2009-09-02 | — | — | EP | disclosed |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1911516-A1 | HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST | Takasago International Corporation (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | disclosed |
| US-5852205-A | Catalytic process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137615-A1 | Homogeneous Asymmetric Hydrogenation Process | HDHD5, HHAT, HVCN1 | NPC1 1764/4885SMN1; SMN2 2953/4885RAB9A 2082/4885 |
| US-20090203927-A1 | Homogeneous asymmetric hydrogenation catalyst | HDHD5, HHAT, HACL2 | NPC1 2029/4885SMN1; SMN2 2876/4885RAB9A 2049/4885 |
| US-20100168440-A1 | Homogeneous Asymmetric Hydrogenation Process | HDHD5, HHAT, HVCN1 | NPC1 1764/4885SMN1; SMN2 2953/4885RAB9A 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.